LONDON (ShareCast) - (ShareCast News) - AIM-listed digital technologies group IXICO has signed a new contract with a North American-based biopharmaceutical company worth £1.2m over a three-year term.
IXICO will provide its technology enabled imaging services in a phase II clinical trial for a treatment for people with Huntington's disease. The company will use its TrialTracker digital platform and scientific services to standardise the acquisition and collection of both MRI and PET scans acquired at specialist imaging centres across North America.

This data will be analysed using IXICO's proprietary image analysis workflows and algorithms to evaluate patient eligibility, monitor patient safety and quantify drug effects.

Chief executive Giulio Cerroni said: "We are delighted to continue our successful track record in Huntington's disease clinical studies, providing compliant data standardisation, collection and analysis to support regulatory submissions. This first contract with a new customer also demonstrates the momentum we are building with our commercially led growth strategy focused on serving the needs of the biopharmaceutical industry."

At 1040 BST, the shares were flat at 33p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE